表紙
市場調查報告書

老齡化性黃斑部病變的基因治療市場:開發中產品分析報告

Gene Therapy for Age-related Macular Degeneration - A Pipeline Analysis Report

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 609185
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
老齡化性黃斑部病變的基因治療市場:開發中產品分析報告 Gene Therapy for Age-related Macular Degeneration - A Pipeline Analysis Report
出版日期: 2018年02月27日內容資訊: 英文 71 Pages
簡介

Technavio的市場調查分析師預測,由於螢光血管攝影等的技術的引進,全球老年性黃斑部病變市場至2020年記錄7%以上的年複合成長率。

本報告提供發展階段及前臨床階段的老年性黃斑部病變的基因治療分子的臨床試驗形勢的詳細洞察。還有治療,給藥途徑,及標的等各種市場區隔為基礎的開發平台分子的治療評估相關全面性資訊。

本報告提供,

  • 調查中的開發平台分子各種階段
  • 老齡化性黃斑部病變的各種發展階段的基因治療分子
  • 現在從事老齡化性黃斑部病變的基因治療分子開發的企業
  • 開發中止的分子
  • 核可藥的主要法規當局:各地區

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 簡介

  • AMD的基因治療:洞察

第5章 主要法規當局

  • 美國
  • 歐洲
  • 日本
  • 澳洲
  • 中國

第6章 開發平台形勢

第7章 比較分析

  • 發現階段的分子
  • 前臨床階段的分子
  • 初期階段(第一階段)分子
  • 惰性中斷的分子

第8章 表示分析

第9章 治療評估(治療方法為基礎)

第10章 治療評估(ROA為基礎)

第11章 治療評估:各標的

第12章 主要企業

  • 活躍的企業:範疇與參數

第13章 附錄

  • 簡稱清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR20668

This pipeline analysis report provides detailed insights into the clinical trials landscape of the gene therapy molecules for age-related macular degeneration in the development and pre-clinical stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Technavio's market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020.

Key questions answered in the report include:

  • What are the different stages of the pipeline molecules under investigation?
  • What are the gene therapy molecules in the various development stages for age-related macular degeneration?
  • What are the companies that are currently involved in the development of gene therapy molecules for age-related macular degeneration?
  • What are the molecules discontinued from development?
  • What are the major regulatory authorities approving drugs in various regions?

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Gene therapy for AMD: An insight

PART 05: MAJOR REGULATORY AUTHORITIES

  • US
  • Europe
  • Japan
  • Australia
  • China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS

  • Discovery stage molecules
  • Pre-clinical stage molecules
  • Early-stage (Phase I) molecules
  • Inactive and discontinued molecules

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)

PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)

PART 11: THERAPEUTIC ASSESSMENT BY TARGET

PART 12: KEY COMPANIES

  • Active companies: Category and parameters

PART 13: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Drug approval process by US FDA
  • Exhibit 02: Pipeline landscape
  • Exhibit 03: Pipeline molecules by vendors
  • Exhibit 04: Pipeline molecules by numbers
  • Exhibit 05: Pipeline molecules by percentage
  • Exhibit 06: Overview: Gene therapy for wAMD
  • Exhibit 07: Overview: GS030
  • Exhibit 08: Overview: ADVM-022/ADVM-032
  • Exhibit 09: Overview: Gene therapy for dAMD
  • Exhibit 10: Overview: A005
  • Exhibit 11: Overview: A006
  • Exhibit 12: Overview: RST-001
  • Exhibit 13: Overview: CERE-120
  • Exhibit 14: Overview: CERE-140
  • Exhibit 15: Overview: OXB-201
  • Exhibit 16: Clinical trials description of OXB-201
  • Exhibit 17: Overview: RGX-314
  • Exhibit 18: Clinical trials description of RGX-314
  • Exhibit 19: Inactive and discontinued molecules by numbers
  • Exhibit 20: Inactive and discontinued molecules
  • Exhibit 21: Analysis by disease type
  • Exhibit 22: Overview of indication
  • Exhibit 23: Assessment by monotherapy products by stagewise
  • Exhibit 24: Assessment by RoA
  • Exhibit 25: Segmentation of pipeline by stage and RoA
  • Exhibit 26: Assessment by target
  • Exhibit 27: Vendor landscape
  • Exhibit 28: Segmentation of companies
  • Exhibit 29: Overview: Adverum
  • Exhibit 30: Overview: AGTC
  • Exhibit 31: Overview: Ceregene
  • Exhibit 32: Overview: Gemini Therapeutics
  • Exhibit 33: Overview: Gensight Biologics
  • Exhibit 34: Overview: MeiraGTx
  • Exhibit 35: Overview: Oxford BioMedica
  • Exhibit 36: Overview: REGENXBIO
  • Exhibit 37: Overview: RetroSense Therapeutics